Mogrify
Latest round
- Series A
Last raised
- Sep 2023
Total raised
- $47M
Investors
- 6
About Mogrify
Based in Cambridge, UK, Mogrify Limited also known as Cell Mogrify develops proprietary cell conversion technology that identifies the optimal combination of transcription factors (in vitro) or small molecules (in vivo) to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell or even a progenitor cell-state. The company was founded in 2016 by Jose Polo, Julian Gough, Owen Rackham. Cell Mogrify has developed a proprietary suite of platform technologies that uses a systematic big-data approach to direct cellular reprogramming and the maintenance of cell identity. The platforms are MOGRIFY® and epiMOGRIFY. The MOGRIFY® is a proprietary direct cellular reprogramming technology used to identify the key regulatory switches, such as an optimal combination of transcription factors, required to drive cell identity. The platform is used by biopharmaceuticals to enhance their stem-cell forward reprogramming methods or bypass the development pathways altogether causing a direct trans-differentiation between a mature cell type to another mature cell type. The epiMOGRIFY is an extension of the MOGRIFY® platform, that is used to identify the optimal culture conditions required to maintain cells and support reprogramming in chemically defined media. It is used by biopharmaceuticals in manufacturing cGMP and improving directed differentiation or transdifferentiation to support the development of scalable off-the-shelf therapies for diseases. The company generates revenue by commercializing its platforms as a business model of internal cell therapy development, co-development partnerships, and licensing of novel cell conversions to partners engaged in cell therapy development and regenerative medicine. Mogrify Ltd. plans to improve its immuno-oncology and ophthalmology programs, continue the platform development and explore cell reprogramming for novel therapeutic applications.
Who invested in Mogrify
6 investors across 4 rounds
See all investors in Mogrify
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Mogrify
Who invested in Mogrify?
Mogrify has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Mogrify raised?
Mogrify has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Mogrify last raise money?
Mogrify's most recent round on record is a Series A, in Sep 2023.
What does Mogrify do?
Based in Cambridge, UK, Mogrify Limited also known as Cell Mogrify develops proprietary cell conversion technology that identifies the optimal combination of transcription factors (in vitro) or small molecules (in vivo) to convert any mature cell type into any other mature cell type without going through a pluripotent stem cell or even a progenitor cell-state.
Where is Mogrify headquartered?
Mogrify is headquartered in Cambridge, UK.
Which VCs invest in companies like Mogrify?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Mogrify's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Mogrify? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.